Compare MRKR & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRKR | MDCX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 26.2M |
| IPO Year | 2010 | N/A |
| Metric | MRKR | MDCX |
|---|---|---|
| Price | $1.56 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.17 | ★ $23.50 |
| AVG Volume (30 Days) | 191.9K | ★ 426.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.92 |
| 52 Week High | $4.07 | $8.90 |
| Indicator | MRKR | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 58.65 |
| Support Level | $1.37 | $1.14 |
| Resistance Level | $1.88 | $1.43 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 54.02 | 91.77 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.